theophylline has been researched along with Amyotrophic Lateral Sclerosis in 4 studies
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
Excerpt | Relevance | Reference |
---|---|---|
"Riluzole clearance was estimated from serum drug concentration measurements followed by Bayesian fitting." | 5.33 | Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. ( Groeneveld, GJ; Guchelaar, HJ; Kalmijn, S; Spieksma, M; van den Berg, LH; van Kan, HJ, 2005) |
"Riluzole clearance was estimated from serum drug concentration measurements followed by Bayesian fitting." | 1.33 | Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. ( Groeneveld, GJ; Guchelaar, HJ; Kalmijn, S; Spieksma, M; van den Berg, LH; van Kan, HJ, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (50.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
van Kan, HJ | 1 |
Groeneveld, GJ | 1 |
Kalmijn, S | 1 |
Spieksma, M | 1 |
van den Berg, LH | 1 |
Guchelaar, HJ | 1 |
Nightingale, SL | 1 |
Schiffman, PL | 1 |
Belsh, JM | 1 |
Khondkarian, OA | 1 |
Gannushkina, IV | 1 |
Zavalishin, IA | 1 |
Zhirnova, IG | 1 |
Nevskaia, OM | 1 |
4 other studies available for theophylline and Amyotrophic Lateral Sclerosis
Article | Year |
---|---|
Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amyotrophic Lateral Sclerosis; Anticonvulsants; Caffe | 2005 |
From the Food and Drug Administration.
Topics: Amyotrophic Lateral Sclerosis; Drug Labeling; Drugs, Investigational; Humans; Product Surveillance, | 1995 |
Effect of inspiratory resistance and theophylline on respiratory muscle strength in patients with amyotrophic lateral sclerosis.
Topics: Airway Resistance; Amyotrophic Lateral Sclerosis; Humans; Middle Aged; Pulmonary Ventilation; Respir | 1989 |
[Immunologic abnormalities in amyotrophic lateral sclerosis].
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antigen-Antibody Complex; B-Lymphocytes; Female; Humans; | 1985 |